British journal of cancer · 1996

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Weaver A, Wrigley E, Watson A, Chang J, Collins CD, Jenkins B, Gill C, Pettengell R, Dexter TM, Testa NG, Crowther D

Аннотация

We have shown that large numbers of haemopoietic progenitor cells are mobilised into the blood after filgrastim [granulocyte colony-stimulating factor (G-CSF)] alone and filgrastim following cyclophosphamide chemotherapy in previously untreated patients with ovarian cancer. These cells may be used to provide safe and effective haemopoietic rescue following dose-intensive chemotherapy. Using filgrastim alone (10 micrograms kg-1), the apheresis harvest contained a median CFU-GM count of 45 x 10(4) kg-1 and 2 x 10(6) kg-1 CD34+ cells. Treatment with filgrastim (5 micrograms kg-1) following cyclophosphamide (3 g m-2) resulted in a harvest containing 66 x 10(4) kg-1 CFU-GM and 2.4 x 10(6) kg-1 CD34+ cells. There was no statistically significant difference between these two mobilising regimens. We have also demonstrated that dose-intensive carboplatin and cyclophosphamide chemotherapy can be delivered safely to patients with ovarian cancer when supported by peripheral blood progenitor cells and filgrastim. Carboplatin (AUC 7.5) and cyclophosphamide (900 mg m-2) given at 3 weekly intervals with progenitor cell and growth factor support was well tolerated in terms of haematological and systemic side-effects. Double the dose intensity of chemotherapy was delivered compared with our standard dose regimen when the treatment was given at 3 weekly intervals. Median dose intensity could be further escalated to 2.33 compared with our standard regimen by decreasing the interval between treatment cycles to 2 weeks. However, at this dose intensity less than a third of patients received their planned treatment on time. All the delays were due to thrombocytopenia.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Andrews R. G. Bartelmez S. H. Knitter G. H. Myerson D. Bernstein I. D. Appelbaum F. R. Zsebo K. M. A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons. 80 4 15 8 1992 920 927 Blood 1379853

Calvert A. H. Newell D. R. Gumbrell L. A. O'Reilly S. Burnell M. Boxall F. E. Siddik Z. H. Judson I. R. Gore M. E. Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. 7 11 11 1989 1748 1756 J Clin Oncol 2681557 10.1200/JCO.1989.7.11.1748

Dührsen U. Villeval J. L. Boyd J. Kannourakis G. Morstyn G. Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. 72 6 12 1988 2074 2081 Blood 3264199

Feremans W. Le Moine F. Ravoet C. Lambermont M. Bastin G. Delville J. P. Pradier O. Dupont E. Capel P. Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. 47 2 10 1994 135 138 Am J Hematol 7522395 10.1002/ajh.2830470214

Gianni A. M. Siena S. Bregni M. Tarella C. Stern A. C. Pileri A. Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. 2 8663 9 9 1989 580 585 Lancet 2570283 10.1016/s0140-6736(89)90711-3

Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. 1988 121 141 Important Adv Oncol 3042601

Kaye S. B. Lewis C. R. Paul J. Duncan I. D. Gordon H. K. Kitchener H. C. Cruickshank D. J. Atkinson R. J. Soukop M. Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. 340 8815 8 8 1992 329 333 Lancet 1353804 10.1016/0140-6736(92)91404-v

Levin L. Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. 5 5 5 1987 756 767 J Clin Oncol 3572465 10.1200/JCO.1987.5.5.756

Murphy D. Crowther D. Renninson J. Prendiville J. Ranson M. Lind M. Patel U. Dougal M. Buckley C. H. Tindall V. R. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. 4 5 5 1993 377 383 Ann Oncol 8353072 10.1093/oxfordjournals.annonc.a058516

Ngan H. Y. Choo Y. C. Cheung M. Wong L. C. Ma H. K. Collins R. Fung C. Ng C. S. Wong V. Ho H. C. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. 35 3 1989 221 227 Chemotherapy 2766862 10.1159/000238673

Parkin D. M. Lärä E. Muir C. S. Estimates of the worldwide frequency of sixteen major cancers in 1980. 41 2 15 2 1988 184 197 Int J Cancer 3338870 10.1002/ijc.2910410205

Russell N. H. Hunter A. Rogers S. Hanley J. Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. 341 8858 5 6 1993 1482 1482 Lancet 8099182 10.1016/0140-6736(93)90929-b

Siena S. Bregni M. Brando B. Belli N. Ravagnani F. Gandola L. Stern A. C. Lansdorp P. M. Bonadonna G. Gianni A. M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. 77 2 15 1 1991 400 409 Blood 1702334

Socinski M. A. Cannistra S. A. Elias A. Antman K. H. Schnipper L. Griffin J. D. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. 1 8596 28 5 1988 1194 1198 Lancet 2897009 10.1016/s0140-6736(88)92012-0

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.

Ошибки и ограничения

Аннотация